Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines

BACKGROUND: The integrase inhibitor dolutegravir is being considered in several countries in sub-Saharan Africa instead of efavirenz for people initiating antiretroviral therapy (ART) because of superior tolerability and a lower risk of resistance emergence. WHO requested updated modelling results f...

Descripción completa

Detalles Bibliográficos
Autores principales: Phillips, Andrew N, Bansi-Matharu, Loveleen, Venter, Francois, Havlir, Diane, Pozniak, Anton, Kuritzkes, Daniel R, Wensing, Annemarie, Lundgren, Jens D, Pillay, Deenan, Mellors, John, Cambiano, Valentina, Jahn, Andreas, Apollo, Tsitsi, Mugurungi, Owen, Ripin, David, Da Silva, Juliana, Raizes, Elliot, Ford, Nathan, Siberry, George K, Gupta, Ravindra K, Barnabas, Ruanne, Revill, Paul, Cohn, Jennifer, Calmy, Alexandra, Bertagnolio, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167509/
https://www.ncbi.nlm.nih.gov/pubmed/32035041
http://dx.doi.org/10.1016/S2352-3018(19)30400-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167509/
https://www.ncbi.nlm.nih.gov/pubmed/32035041
http://dx.doi.org/10.1016/S2352-3018(19)30400-X

Ejemplares similares